ECM
VRTX icon

ExodusPoint Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

ExodusPoint Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,403
Closed -$10M – 2120
2026
Q1 		$10M Buy
+22,403
New +$10.4M 0.08% 234
2025
Q1 		– Sell
-22,794
Closed -$9.18M – 2041
2024
Q4 		$9.18M Buy
+22,794
New +$10.6M 0.06% 289
2024
Q2 		– Sell
-52,300
Closed -$21.9M – 2018
2024
Q1 		$21.9M Buy
+52,300
New +$22.1M 0.17% 94
2023
Q2 		– Sell
-64,541
Closed -$20.3M – 2280
2023
Q1 		$20.3M Buy
64,541
+34,073
+112% +$10.2M 0.17% 104
2022
Q4 		$8.8M Buy
+30,468
New +$9.29M 0.13% 201
2022
Q3 		– Sell
-3,751
Closed -$1.06M – 2336
2022
Q2 		$1.06M Buy
+3,751
New +$1M 0.01% 1055
2022
Q1 		– Sell
-44,933
Closed -$9.87M – 2716
2021
Q4 		$9.87M Buy
44,933
+5,821
+15% +$1.13M 0.1% 223
2021
Q3 		$7.09M Buy
39,112
+13,450
+52% +$2.63M 0.1% 284
2021
Q2 		$5.17M Buy
25,662
+16,065
+167% +$3.36M 0.06% 341
2021
Q1 		$2.06M Sell
9,597
-9,316
-49% -$2.05M 0.03% 563
2020
Q4 		$4.47M Buy
18,913
+12,091
+177% +$2.77M 0.04% 282
2020
Q3 		$1.86M Sell
6,822
-7,786
-53% -$2.15M 0.04% 434
2020
Q2 		$4.24M Buy
14,608
+12,370
+553% +$3.35M 0.11% 188
2020
Q1 		$533K Buy
+2,238
New +$513K 0.03% 462
2019
Q4 		– Sell
-8,776
Closed -$1.49M – 1913
2019
Q3 		$1.49M Buy
8,776
+1,956
+29% +$346K 0.05% 296
2019
Q2 		$1.25M Buy
+6,820
New +$1.19M 0.05% 221

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ExodusPoint Capital Management's VRTX Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 22,403 shares — an estimated $10M sold.

ExodusPoint Capital Management first reported a position in VRTX in Q2 2019 and held it in 16 quarters. The position peaked at $21.9M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 22,403 Vertex Pharmaceuticals shares in Q2 2026, an estimated $10M.
  • ExodusPoint Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 16 quarters.
  • ExodusPoint Capital Management's Vertex Pharmaceuticals position peaked at $21.9M in Q1 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.